JP2019533684A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019533684A5 JP2019533684A5 JP2019522381A JP2019522381A JP2019533684A5 JP 2019533684 A5 JP2019533684 A5 JP 2019533684A5 JP 2019522381 A JP2019522381 A JP 2019522381A JP 2019522381 A JP2019522381 A JP 2019522381A JP 2019533684 A5 JP2019533684 A5 JP 2019533684A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- combination
- leucovorin
- irinotecan
- oxaliplatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 229960004768 irinotecan Drugs 0.000 claims description 62
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 62
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 claims description 46
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 claims description 46
- 235000008191 folinic acid Nutrition 0.000 claims description 46
- 239000011672 folinic acid Substances 0.000 claims description 46
- 229960001691 leucovorin Drugs 0.000 claims description 46
- 239000002502 liposome Substances 0.000 claims description 44
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 38
- 229960002949 fluorouracil Drugs 0.000 claims description 38
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 38
- 229960001756 oxaliplatin Drugs 0.000 claims description 38
- 238000002560 therapeutic procedure Methods 0.000 claims description 35
- 230000000259 anti-tumor effect Effects 0.000 claims description 34
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 22
- 206010017758 gastric cancer Diseases 0.000 claims description 22
- 201000011549 stomach cancer Diseases 0.000 claims description 22
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 14
- 235000012000 cholesterol Nutrition 0.000 claims description 7
- WEPNHBQBLCNOBB-FZJVNAOYSA-N sucrose octasulfate Chemical compound OS(=O)(=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@H](COS(=O)(=O)O)O[C@]1(COS(O)(=O)=O)O[C@@H]1[C@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H](COS(O)(=O)=O)O1 WEPNHBQBLCNOBB-FZJVNAOYSA-N 0.000 claims description 7
- 238000001802 infusion Methods 0.000 claims description 6
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 230000003457 anti-vomiting effect Effects 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 239000002895 emetic Substances 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 6
- 229920001223 polyethylene glycol Polymers 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims 2
- 150000003904 phospholipids Chemical class 0.000 claims 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 1
- 229920002505 N-(Carbonyl-Methoxypolyethylene Glycol 2000)-1,2-Distearoyl-Sn-Glycero-3-Phosphoethanolamine Polymers 0.000 claims 1
- RZBMBMLIIRIAMH-LDLOPFEMSA-N [(2R)-2,3-dihydroxypropyl] 2-[di(octadecanoyl)amino]ethyl hydrogen phosphate Chemical compound C(CCCCCCCCCCCCCCCCC)(=O)N(CCOP(OC[C@@H](CO)O)(=O)O)C(CCCCCCCCCCCCCCCCC)=O RZBMBMLIIRIAMH-LDLOPFEMSA-N 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 125000001095 phosphatidyl group Chemical group 0.000 claims 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims 1
- SRLOHQKOADWDBV-NRONOFSHSA-M sodium;[(2r)-2,3-di(octadecanoyloxy)propyl] 2-(2-methoxyethoxycarbonylamino)ethyl phosphate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCCNC(=O)OCCOC)OC(=O)CCCCCCCCCCCCCCCCC SRLOHQKOADWDBV-NRONOFSHSA-M 0.000 claims 1
- 238000000034 method Methods 0.000 description 33
- 229960005277 gemcitabine Drugs 0.000 description 5
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 5
- 206010061818 Disease progression Diseases 0.000 description 1
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- KLEAIHJJLUAXIQ-JDRGBKBRSA-N irinotecan hydrochloride hydrate Chemical compound O.O.O.Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 KLEAIHJJLUAXIQ-JDRGBKBRSA-N 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229940048191 onivyde Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022146925A JP2022171808A (ja) | 2016-11-02 | 2022-09-15 | リポソームイリノテカン、オキサリプラチン、５－フルオロウラシル（およびロイコボリン）を含む併用療法を用いる胃がんの処置 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662416317P | 2016-11-02 | 2016-11-02 | |
| US62/416,317 | 2016-11-02 | ||
| PCT/GB2017/053293 WO2018083470A1 (en) | 2016-11-02 | 2017-11-01 | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluoruracil (and leucovorin) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022146925A Division JP2022171808A (ja) | 2016-11-02 | 2022-09-15 | リポソームイリノテカン、オキサリプラチン、５－フルオロウラシル（およびロイコボリン）を含む併用療法を用いる胃がんの処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019533684A JP2019533684A (ja) | 2019-11-21 |
| JP2019533684A5 true JP2019533684A5 (OSRAM) | 2020-12-10 |
Family
ID=60569939
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019522381A Ceased JP2019533684A (ja) | 2016-11-02 | 2017-11-01 | リポソームイリノテカン、オキサリプラチン、５−フルオロウラシル（およびロイコボリン）を含む併用療法を用いる胃がんの処置 |
| JP2022146925A Pending JP2022171808A (ja) | 2016-11-02 | 2022-09-15 | リポソームイリノテカン、オキサリプラチン、５－フルオロウラシル（およびロイコボリン）を含む併用療法を用いる胃がんの処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022146925A Pending JP2022171808A (ja) | 2016-11-02 | 2022-09-15 | リポソームイリノテカン、オキサリプラチン、５－フルオロウラシル（およびロイコボリン）を含む併用療法を用いる胃がんの処置 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11071726B2 (OSRAM) |
| EP (1) | EP3535026A1 (OSRAM) |
| JP (2) | JP2019533684A (OSRAM) |
| KR (1) | KR20190077441A (OSRAM) |
| CN (1) | CN110402163A (OSRAM) |
| AU (1) | AU2017354903B2 (OSRAM) |
| BR (1) | BR112019007844A2 (OSRAM) |
| CA (1) | CA3040395A1 (OSRAM) |
| EA (1) | EA201990979A1 (OSRAM) |
| IL (2) | IL266187A (OSRAM) |
| MA (1) | MA46709A (OSRAM) |
| MX (1) | MX392408B (OSRAM) |
| MY (1) | MY202377A (OSRAM) |
| PH (1) | PH12019500892A1 (OSRAM) |
| RU (1) | RU2761953C2 (OSRAM) |
| SG (2) | SG11201903615WA (OSRAM) |
| TW (1) | TWI791467B (OSRAM) |
| WO (1) | WO2018083470A1 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2821167C (en) * | 2004-05-03 | 2016-06-28 | Merrimack Pharmaceuticals, Inc. | Drug delivery liposomes containing anionic polyols or anionic sugars |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| US11318131B2 (en) | 2015-05-18 | 2022-05-03 | Ipsen Biopharm Ltd. | Nanoliposomal irinotecan for use in treating small cell lung cancer |
| ES2848118T3 (es) | 2015-08-20 | 2021-08-05 | Ipsen Biopharm Ltd | Terapia de combinación que usa irinotecán liposomal y un inhibidor de PARP para el tratamiento del cáncer |
| KR102714060B1 (ko) | 2015-08-21 | 2024-10-08 | 입센 바이오팜 리미티드 | 리포솜 이리노테칸 및 옥살리플라틴을 포함하는 병용 치료를 이용하여 전이성 췌장암을 치료하는 방법 |
| WO2017066726A1 (en) | 2015-10-16 | 2017-04-20 | Merrimack Pharmaceuticals, Inc. | Stabilizing camptothecin pharmaceutical compositions |
| BR112019007844A2 (pt) | 2016-11-02 | 2019-07-16 | Ipsen Biopharm Ltd | tratamento de câncer gástrico usando terapias de combinação compreendendo irinotecano lipossômico, oxaliplatina, 5-fluoroacila (e leucovorina) |
| AU2018246024B2 (en) | 2017-03-31 | 2020-08-06 | Fujifilm Corporation | Liposome composition and pharmaceutical composition |
| EP3811931B1 (en) | 2018-06-20 | 2024-07-03 | FUJIFILM Corporation | Combination medication containing liposome composition encapsulating drug and immune checkpoint inhibitor |
| EP3861987A4 (en) | 2018-10-01 | 2021-09-15 | FUJIFILM Corporation | COMBINATION DRUG CONTAINING A LIPOSOME COMPOSITION ENCAPSULATING A DRUG AND A PLATINUM PREPARATION |
| BR112021007318A2 (pt) * | 2018-10-17 | 2021-08-31 | Biolinerx Ltd. | Tratamento de adenocarcinoma pancreático metastático |
| WO2020148744A1 (en) * | 2019-01-17 | 2020-07-23 | Biolinerx Ltd. | Combination therapy for treatment of pancreatic cancer |
| EP3911353A1 (en) * | 2019-01-17 | 2021-11-24 | BioLineRx Ltd. | Specific combination therapy for treatment of pancreatic cancer |
| WO2020170164A1 (en) * | 2019-02-22 | 2020-08-27 | Moshe Giladi | Treating gastric cancer using ttfields combined with xelox or folfox |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
| US5077056A (en) | 1984-08-08 | 1991-12-31 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
| JPH0720857B2 (ja) | 1988-08-11 | 1995-03-08 | テルモ株式会社 | リポソームおよびその製法 |
| IL91664A (en) | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5538954A (en) | 1994-06-24 | 1996-07-23 | A/S Dumex (Dumex Ltd.) | Salts of tetracyclines |
| US5783568A (en) | 1994-06-10 | 1998-07-21 | Sugen, Inc. | Methods for treating cancer and other cell proliferative diseases |
| US5543152A (en) | 1994-06-20 | 1996-08-06 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US5800833A (en) | 1995-02-27 | 1998-09-01 | University Of British Columbia | Method for loading lipid vesicles |
| DE19605024A1 (de) | 1996-01-31 | 1997-08-07 | Schering Ag | Neue selektive Taxane, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung |
| US5997899A (en) | 1996-10-01 | 1999-12-07 | Skyepharma Inc. | Method for producing liposomes with increased percent of compound encapsulated |
| US6110491A (en) | 1996-10-22 | 2000-08-29 | Hermes Biosciences, Inc. | Compound-loaded liposomes and methods for their preparation |
| US6210707B1 (en) | 1996-11-12 | 2001-04-03 | The Regents Of The University Of California | Methods of forming protein-linked lipidic microparticles, and compositions thereof |
| US6787132B1 (en) | 1997-12-04 | 2004-09-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Combined chemo-immunotherapy with liposomal drugs and cytokines |
| US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
| US6726925B1 (en) | 1998-06-18 | 2004-04-27 | Duke University | Temperature-sensitive liposomal formulation |
| BR9914601A (pt) | 1998-09-16 | 2001-10-23 | Alza Corp | Inibidor de topoisomerase capturado por lipossoma |
| US7311924B2 (en) | 1999-04-01 | 2007-12-25 | Hana Biosciences, Inc. | Compositions and methods for treating cancer |
| WO2000066125A1 (en) | 1999-04-29 | 2000-11-09 | Aventis Pharma S.A. | Method for treating cancer using camptothecin derivatives and 5-fluorouracil |
| US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
| US6511676B1 (en) | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
| EP1259225B1 (en) | 2000-02-04 | 2006-10-04 | Lipoxen Technologies Limited | Process of dehydration/rehydration for making liposomes |
| US6545010B2 (en) | 2000-03-17 | 2003-04-08 | Aventis Pharma S.A. | Composition comprising camptothecin or a camptothecin derivative and a platin derivative for the treatment of cancer |
| DE60118547T2 (de) | 2000-05-15 | 2007-02-01 | Celgene Corp. | Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält |
| AU2001270385B2 (en) | 2000-06-30 | 2006-05-25 | Talon Therapeutics, Inc. | Liposomal antineoplastic drugs and uses thereof |
| TWI283575B (en) | 2000-10-31 | 2007-07-11 | Eisai Co Ltd | Medicinal compositions for concomitant use as anticancer agent |
| US7108863B2 (en) | 2001-03-26 | 2006-09-19 | Alza Corporation | Liposome composition for improved intracellular delivery of a therapeutic agent |
| US7219016B2 (en) | 2001-04-20 | 2007-05-15 | Yale University | Systems and methods for automated analysis of cells and tissues |
| WO2003030864A1 (en) | 2001-05-29 | 2003-04-17 | Neopharm, Inc. | Liposomal formulation of irinotecan |
| AU2002328952A1 (en) | 2001-07-23 | 2003-02-24 | Epidauros Biotechnologie Ag | Irinotecan for treatment of cancer |
| US7850990B2 (en) | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| CA2752143C (en) | 2002-05-15 | 2014-09-23 | Sutter West Bay Hospitals | Delivery of nucleic acid-like compounds |
| MXPA04011871A (es) | 2002-05-31 | 2005-07-26 | Transmolecular Inc | Quimioterapia en combinacion con clorotoxina. |
| WO2004035032A2 (en) | 2002-08-20 | 2004-04-29 | Neopharm, Inc. | Pharmaceutical formulations of camptothecine derivatives |
| RS20150135A1 (sr) | 2003-05-30 | 2015-08-31 | Genentech Inc. | Tretman sa anti-vegf antitelima |
| US8658203B2 (en) | 2004-05-03 | 2014-02-25 | Merrimack Pharmaceuticals, Inc. | Liposomes useful for drug delivery to the brain |
| CA2821167C (en) | 2004-05-03 | 2016-06-28 | Merrimack Pharmaceuticals, Inc. | Drug delivery liposomes containing anionic polyols or anionic sugars |
| KR100889139B1 (ko) * | 2004-06-01 | 2009-03-17 | 테루모 가부시키가이샤 | 이리노테칸 제제 |
| JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
| TWI375673B (en) | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| WO2007050784A2 (en) | 2005-10-25 | 2007-05-03 | Celator Pharmaceuticals, Inc. | Fixed ratio drug combination treatments for solid tumors |
| EP1976485A4 (en) | 2005-12-22 | 2011-10-26 | Celator Pharmaceuticals Inc | LIPOSOMAL FORMULATIONS WITH SECONDARY AND TERTIARY AMINES AND METHOD OF MANUFACTURING THEREOF |
| RS53082B (sr) | 2006-01-17 | 2014-06-30 | Abbvie Bahamas Ltd. | Kombinovana terapija sa parp inhibitorima |
| CN101442998B (zh) | 2006-03-16 | 2012-03-14 | 比奥纽默里克药物公司 | 抗癌活性加强化合物和制剂及其用法 |
| SI2716301T1 (sl) | 2007-02-16 | 2017-07-31 | Merrimack Pharmaceuticals, Inc. | Protitelesa proti ErbB3 in uporaba le-teh |
| US20120003160A1 (en) | 2007-06-29 | 2012-01-05 | Amag Pharmaceuticals, Inc. | Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session |
| EP2187869B1 (en) | 2007-08-17 | 2015-10-14 | Celator Pharmaceuticals, Inc. | Improved platinum drug formulations |
| EP2197917A1 (en) | 2007-09-28 | 2010-06-23 | Universitätsspital Basel | Immunoliposomes for treatment of cancer |
| NZ586123A (en) | 2007-11-12 | 2012-12-21 | Bipar Sciences Inc | Treatment of ovarian cancer with 4-iodo-3-nitrobenzamide in combination with topoisomerase inhibitors |
| RU2010128107A (ru) | 2007-12-07 | 2012-01-20 | Байпар Сайенсиз, Инк. (Us) | Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp |
| CA2718918A1 (en) | 2008-03-25 | 2009-11-26 | Schering Corporation | Methods for treating or preventing colorectal cancer |
| US8067432B2 (en) | 2008-03-31 | 2011-11-29 | University Of Kentucky Research Foundation | Liposomal, ring-opened camptothecins with prolonged, site-specific delivery of active drug to solid tumors |
| KR20110008086A (ko) | 2008-04-11 | 2011-01-25 | 메리맥 파마슈티컬즈, 인크. | 인간 혈청 알부민 링커 및 그 콘쥬게이트 |
| US8852630B2 (en) | 2008-05-13 | 2014-10-07 | Yale University | Chimeric small molecules for the recruitment of antibodies to cancer cells |
| JP5677972B2 (ja) | 2008-11-18 | 2015-02-25 | メリマック ファーマシューティカルズ インコーポレーティッド | ヒト血清アルブミンリンカーおよびそのコンジュゲート |
| WO2010125462A2 (en) | 2009-05-01 | 2010-11-04 | Oncozyme Pharma Inc. | Pentamidine combinations for treating cancer |
| WO2011066684A1 (zh) | 2009-12-03 | 2011-06-09 | 江苏恒瑞医药股份有限公司 | 伊立替康或盐酸伊立替康脂质体及其制备方法 |
| KR20130088116A (ko) | 2010-06-04 | 2013-08-07 | 아브락시스 바이오사이언스, 엘엘씨 | 췌장암의 치료 방법 |
| WO2012012448A1 (en) | 2010-07-19 | 2012-01-26 | Bipar Sciences, Inc. | Methods of treating breast cancer using 4-iodo-3-nitrobenzamide in combination with anti-tumor agents |
| WO2012012759A2 (en) | 2010-07-22 | 2012-01-26 | The Regents Of The University Of California | Anti-tumor antigen antibodies and methods of use |
| RU2541100C2 (ru) | 2010-09-03 | 2015-02-10 | Боард Оф Регентс Оф Зе Юниверсити Оф Небраска | Способ и композиция для лечения рака |
| EP2648738A2 (en) | 2010-12-06 | 2013-10-16 | Merrimack Pharmaceuticals, Inc. | Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracyclin chemotherapeutic agents |
| CA2821024A1 (en) | 2010-12-14 | 2012-06-21 | Technical University Of Denmark | Entrapment of radionuclides in nanoparticle compositions |
| EP2675918B1 (en) | 2011-02-15 | 2017-11-08 | Merrimack Pharmaceuticals, Inc. | Compositions and methods for delivering nucleic acid to a cell |
| AU2012245491C1 (en) | 2011-04-19 | 2017-12-21 | Merrimack Pharmaceuticals, Inc. | Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies |
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
| WO2013138371A1 (en) * | 2012-03-12 | 2013-09-19 | Merrimack Pharmaceuticals, Inc. | Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody |
| AU2013249307B2 (en) | 2012-04-17 | 2017-11-09 | Merrimack Pharmaceuticals, Inc. | Compositions and methods for non-invasive imaging |
| US9717724B2 (en) | 2012-06-13 | 2017-08-01 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies |
| AU2013202947B2 (en) * | 2012-06-13 | 2016-06-02 | Ipsen Biopharm Ltd. | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan |
| AU2013374248A1 (en) | 2012-12-14 | 2015-06-11 | Merrimack Pharmaceuticals, Inc. | Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agents |
| DK2979700T3 (en) | 2013-03-27 | 2019-01-21 | Taiho Pharmaceutical Co Ltd | ANTITUMUM AGENT CONTAINING A LOW IRINOTECAN HYDROCHLORIDE HYDRATE |
| WO2015031536A1 (en) | 2013-08-27 | 2015-03-05 | Northeastern University | Nanoparticle drug delivery system and method of treating cancer and neurotrauma |
| WO2015061592A1 (en) | 2013-10-23 | 2015-04-30 | Merrimack Pharmaceuticals, Inc. | Liposomes for non-invasive imaging and drug delivery |
| JP7113619B2 (ja) | 2014-12-09 | 2022-08-05 | イプセン バイオファーム リミティド | リポソーマルイリノテカンによる乳がんの治療 |
| TW201701880A (zh) | 2015-04-14 | 2017-01-16 | 莫瑞麥克製藥公司 | 改善持續釋放藥物治療之藥物動力學及治療指數之方法 |
| ES2848118T3 (es) | 2015-08-20 | 2021-08-05 | Ipsen Biopharm Ltd | Terapia de combinación que usa irinotecán liposomal y un inhibidor de PARP para el tratamiento del cáncer |
| KR102714060B1 (ko) | 2015-08-21 | 2024-10-08 | 입센 바이오팜 리미티드 | 리포솜 이리노테칸 및 옥살리플라틴을 포함하는 병용 치료를 이용하여 전이성 췌장암을 치료하는 방법 |
| WO2017066726A1 (en) | 2015-10-16 | 2017-04-20 | Merrimack Pharmaceuticals, Inc. | Stabilizing camptothecin pharmaceutical compositions |
| US20170202840A1 (en) | 2016-01-14 | 2017-07-20 | Merrimack Pharmaceuticals, Inc. | Treatment of pancreatic cancer with liposomal irinotecan |
| WO2017172678A1 (en) | 2016-03-30 | 2017-10-05 | Merrimack Pharmaceuticals, Inc. | Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan |
| MX394766B (es) | 2016-05-18 | 2025-03-24 | Ipsen Biopharm Ltd | Irinotecan nanoliposomico para usarse en el tratamiento del cancer de pulmon de celulas pequeñas. |
| US20170333421A1 (en) | 2016-05-18 | 2017-11-23 | Ipsen Biopharm Ltd. | Population Pharmacokinetics of Liposomal Irinotecan |
| BR112019007844A2 (pt) | 2016-11-02 | 2019-07-16 | Ipsen Biopharm Ltd | tratamento de câncer gástrico usando terapias de combinação compreendendo irinotecano lipossômico, oxaliplatina, 5-fluoroacila (e leucovorina) |
-
2017
- 2017-11-01 BR BR112019007844A patent/BR112019007844A2/pt not_active IP Right Cessation
- 2017-11-01 EP EP17808557.7A patent/EP3535026A1/en not_active Ceased
- 2017-11-01 WO PCT/GB2017/053293 patent/WO2018083470A1/en not_active Ceased
- 2017-11-01 US US16/346,436 patent/US11071726B2/en not_active Expired - Fee Related
- 2017-11-01 SG SG11201903615WA patent/SG11201903615WA/en unknown
- 2017-11-01 RU RU2019114952A patent/RU2761953C2/ru active
- 2017-11-01 CN CN201780080584.XA patent/CN110402163A/zh active Pending
- 2017-11-01 SG SG10201912338RA patent/SG10201912338RA/en unknown
- 2017-11-01 EA EA201990979A patent/EA201990979A1/ru unknown
- 2017-11-01 CA CA3040395A patent/CA3040395A1/en active Pending
- 2017-11-01 MX MX2019004783A patent/MX392408B/es unknown
- 2017-11-01 KR KR1020197014970A patent/KR20190077441A/ko not_active Ceased
- 2017-11-01 JP JP2019522381A patent/JP2019533684A/ja not_active Ceased
- 2017-11-01 AU AU2017354903A patent/AU2017354903B2/en active Active
- 2017-11-01 MY MYPI2019002087A patent/MY202377A/en unknown
- 2017-11-01 MA MA046709A patent/MA46709A/fr unknown
- 2017-11-01 TW TW106137766A patent/TWI791467B/zh active
-
2019
- 2019-04-23 IL IL266187A patent/IL266187A/en unknown
- 2019-04-24 PH PH12019500892A patent/PH12019500892A1/en unknown
-
2022
- 2022-03-24 IL IL291679A patent/IL291679A/en unknown
- 2022-09-15 JP JP2022146925A patent/JP2022171808A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019533684A5 (OSRAM) | ||
| JP2018528185A5 (OSRAM) | ||
| He et al. | Liposomes and liposome-like nanoparticles: From anti-fungal infection to the COVID-19 pandemic treatment | |
| RU2019114952A (ru) | Способы лечения рака желудочно-кишечного тракта с применением комбинационных видов терапии, содержащих липосомальный иринотекан и оксалиплатин | |
| JP2015523355A5 (OSRAM) | ||
| JP2018528184A5 (OSRAM) | ||
| JP5890780B2 (ja) | 中枢を介する悪心および嘔吐を治療するための組成物および方法 | |
| JP5543956B2 (ja) | 癌の処置のための方法および組成物 | |
| RU2018105666A (ru) | Способы лечения метастатического рака поджелудочной железы с помощью комбинированной терапии, включающей применение иринотекана и оксалиплатина | |
| JP2014088444A5 (OSRAM) | ||
| JP2019504100A5 (OSRAM) | ||
| FI3821887T3 (fi) | Mitoksantroni liposomin käyttö ei-hodgkinin lymfooman hoitoon | |
| JP2017081920A (ja) | サキシトキシン誘導体での触覚の喪失の処置 | |
| JP7015237B2 (ja) | 腫瘍の成長を抑制する方法 | |
| PH12018502422A1 (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer | |
| JP2021509395A5 (OSRAM) | ||
| JP2019501881A5 (OSRAM) | ||
| JP2008540364A5 (OSRAM) | ||
| CN102438608A (zh) | 包含ave8062和索拉非尼的抗肿瘤组合 | |
| DE60025494T2 (de) | Epothilon zusammensetzungen | |
| JP2008517991A5 (OSRAM) | ||
| WO2001083020A1 (en) | Antineoplastic platinum therapeutic method and composition | |
| WO2016122288A3 (ko) | 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제 | |
| Leighl et al. | Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer | |
| JP2019525924A5 (OSRAM) |